Sustained-release postbiotic vaginal insert for anti-candida treatment
A novel sustained-release vaginal insert formulation utilizing postbiotics to combat recurrent vaginal yeast infections. The product aims to reduce antimicrobial resistance while providing soothing properties and synergistic effects with common antifungals.
Overview
The sustained-release postbiotic vaginal insert is designed to address recurrent vaginal yeast infections caused by Candida species. This innovative solution leverages the anti-Candida and anti-Candida biofilm properties of postbiotics derived from Lactobacillus spp. and Bacillus spp., known for their Generally Recognized As Safe (GRAS) status. By incorporating soothing prebiotics, the formulation aims to restore the natural vaginal microbiota balance, reduce itchiness, and enhance comfort. This product also offers a strategic advantage in reducing antimicrobial resistance by potentially working synergistically with established antifungal agents like clotrimazole and nystatin.
Technical specifications
- Sustained-release formulation: Ensures prolonged efficacy and enhanced therapeutic outcomes.
- Postbiotic components: Derived from Lactobacillus spp. and Bacillus spp., targeting Candida albicans and its biofilms.
- Soothing prebiotics: Added to restore natural microbiota balance and provide comfort.
- Compatibility with antifungals: Designed to work with clotrimazole and nystatin, enhancing treatment effectiveness.
Technology readiness level
Currently at TRL 4, the technology has been validated in the lab for its anti-Candida activities. Further validation will involve testing the formulation's efficacy in combination with antifungals and evaluating its stability and release profile. A 1.5-year study is planned, followed by a year of feasibility and safety testing in animal models.
About Lipidware Sdn Bhd
Lipidware Sdn Bhd is a Malaysian biotechnology company founded in 2017 as a university startup from Universiti Putra Malaysia (UPM) through the Putra Science Park InnoHub Programme. The company specializes in translating academic research into commercialized skincare solutions, most notably its REMDII brand. Developed by researchers in biotechnology and biochemistry, the company’s core innovation involves a patented bioactive delivery system that utilizes full-spectrum tocotrienols—a form of Vitamin E—to provide targeted anti-inflammatory and barrier-repair properties for sensitive and eczema-prone skin. This research-driven approach includes rigorous independent testing and ethics-approved human clinical trials to ensure safety and efficacy as a steroid-free alternative for individuals of all ages.
Beyond product development, Lipidware plays a significant role in community education and support through the Malaysia Eczema Support Community (MESC), which provides resources and guidance for patients and caregivers. The company’s efforts bridge the gap between clinical science and practical health management, addressing skin conditions such as atopic dermatitis, psoriasis, and actinic keratosis. Through its commitment to real science, Lipidware has earned numerous national and international accolades for innovation and commercialization, successfully moving university-backed breakthroughs from the laboratory to pharmacy shelves to improve patient quality of life.
delivered to your inbox.